<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875834</url>
  </required_header>
  <id_info>
    <org_study_id>D9480C00002</org_study_id>
    <nct_id>NCT02875834</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia</brief_title>
  <acronym>HARMONIZE GL</acronym>
  <official_title>A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS, in Patients With Hyperkalemia-HARMONIZE Global</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once&#xD;
      daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having&#xD;
      achieved normokalemia following two days of initial ZS therapy (10g TID).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Actual">February 14, 2018</completion_date>
  <primary_completion_date type="Actual">February 14, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Square Mean S-K Level on Days 8-29</measure>
    <time_frame>Through 28-day randomized treatment study phase day 8-29.</time_frame>
    <description>Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29. The results in the table below are presented for RTP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving Normokalemia</measure>
    <time_frame>Through 48-hour initial phase.</time_frame>
    <description>Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours. The results in the table below are presented for OLP. (h=hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exponential Rate of Change in S-K Levels</measure>
    <time_frame>Through 48-hour initial phase.</time_frame>
    <description>Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase. The results in the table below are presented for OLP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in S-K Levels</measure>
    <time_frame>Through 48-hour initial phase.</time_frame>
    <description>Absolute change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in S-K Levels</measure>
    <time_frame>Through 48-hour initial phase.</time_frame>
    <description>Percentage change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Remaining Normokalemic</measure>
    <time_frame>Through 28-day randomized treatment study phase day 8-29.</time_frame>
    <description>The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Normokalemic Patients at Day 1 Through Day 29/Exit</measure>
    <time_frame>Through 28-day randomized treatment phase.</time_frame>
    <description>The proportion of patients who are normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at Day 1 through Day 29/Exit in randomization phase. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Patients Remain Normokalemic</measure>
    <time_frame>Through 28-day randomized treatment phase.</time_frame>
    <description>The number of days patients remain normokalemic during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in S-K Levels</measure>
    <time_frame>Through 28-day randomized treatment phase.</time_frame>
    <description>The mean change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change in S-K Levels</measure>
    <time_frame>Through 28-day randomized treatment phase.</time_frame>
    <description>The mean percentage change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hyperkalemic Patients</measure>
    <time_frame>Through 28-day randomized treatment phase.</time_frame>
    <description>The results represent number of hyperkalemic patients during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in S-Aldosterone and P Renin Levels</measure>
    <time_frame>Through 28-day randomized treatment phase.</time_frame>
    <description>The mean changes from OLP baseline in S-Aldosterone and P-Renin levels. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Health State (EQ-5D) Questionnaire</measure>
    <time_frame>Through study completion, an average of 37 days.</time_frame>
    <description>Evaluate health state of patients using EQ-5D questionnaire. This scale is numbered from 0 to 100. 0 means the worst health you can imagine. 100 means the best health you can imagine. The results in the table below are presented for RTP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 10g</intervention_name>
    <description>Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 5g</intervention_name>
    <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 5g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 10g</intervention_name>
    <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Female and male patients aged ≥18 and ≤ 90 years&#xD;
&#xD;
          -  Two consecutive i-STAT potassium values, measured 60-minutes (± 10 minutes) apart,&#xD;
             both ≥ 5.1 mmol/l and measured within 1 day of the first ZS dose on 48-hour open-label&#xD;
             initial phase Day 1&#xD;
&#xD;
          -  Ability to have repeated blood draws or effective venous catheterization&#xD;
&#xD;
          -  Female patients must be 1 year post-menopausal, surgically sterile, or using an&#xD;
             acceptable method of contraception for the duration of the study and for 3 months&#xD;
             after the last dose of ZS/matching placebo to prevent pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 3 months&#xD;
&#xD;
          -  Pseudohyperkalemia signs and symptoms&#xD;
&#xD;
          -  Patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed antibiotics&#xD;
             for hyperammonemia within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Patients treated with resins,calcium acetate,calcium carbonate, or lanthanum&#xD;
             carbonate,within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Patients with a life expectancy of less than 3 months&#xD;
&#xD;
          -  Patients who are severely physically or mentally incapacitated and who in the opinion&#xD;
             of investigator are unable to perform the subjects' tasks associated with the protocol&#xD;
&#xD;
          -  Female patients who are pregnant, lactating, or planning to become pregnant&#xD;
&#xD;
          -  Patients with diabetic ketoacidosis&#xD;
&#xD;
          -  Presence of any condition which, in the opinion of the investigator, places the&#xD;
             patient at undue risk or potentially jeopardizes the quality of the data to be&#xD;
             generated&#xD;
&#xD;
          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof&#xD;
&#xD;
          -  Patients with cardiac arrhythmias that require immediate treatment&#xD;
&#xD;
          -  Patients on dialysis&#xD;
&#xD;
          -  Patients who are blood donors should not donate blood during the study and for 3&#xD;
             months following their last dose of ZS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanyu-shi</city>
        <zip>348-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachinaka-shi</city>
        <zip>312-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ina-shi</city>
        <zip>396-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <zip>306-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsudo-shi</city>
        <zip>271-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>462-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimajiri-gun</city>
        <zip>901-0493</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka-shi</city>
        <zip>421-0117</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toride-shi</city>
        <zip>302-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyohashi-shi</city>
        <zip>441-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yao-shi</city>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang-si</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <zip>14647</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10444</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hwaseong-si</city>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uijeongbu-si</city>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju-si</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hualien City</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Taipei</city>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>ROC 100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4401&amp;filename=d9480c00002-sap-ed-2_Redacted_CTT.PDF</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4401&amp;filename=d9480c00002-csp-v3_Redacted_CTT.PDF</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <results_first_submitted>February 12, 2019</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02875834/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02875834/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in 42 centers within Japan, Russia, South Korea, and Taiwan.</recruitment_details>
      <pre_assignment_details>the study consisted of two phases: an open-label phase (single arm, 48 hours, ZS 10 g TID; OLP) and a randomized treatment phase (3 arms, 28 days; RTP). 267 patients entered OLP. Out of these, 248 endered RTP and were randomized to placebo, ZS 5 g QD or ZS 10 g QD in a 1:2:2 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
          <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="P2">
          <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
          <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="P3">
          <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
          <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>(Not collected)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomized Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No subjects were randomized in 10g TID group in RTP.</participants>
                <participants group_id="P2" count="99">99 subjects were randomized in 5g QD group in RTP.</participants>
                <participants group_id="P3" count="99">99 subjects were randomized in 10g QD group in RTP.</participants>
                <participants group_id="P4" count="50">50 subjects were randomized in placebo group in RTP.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>(Not collected)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In RTP there were no subjects analyzed in Sodium Zirconium Cyclosilicate (ZS) 10g tid arm. In OLP, only ZS 10 g TID arm was present. All subjects in RTP took part in OLP.</population>
      <group_list>
        <group group_id="B1">
          <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
          <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="B2">
          <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
          <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="B3">
          <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
          <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="267"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="515"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All subjects in RTP took part in OLP. Thus, the Totals are calculated using replicated measurements.</description>
          <population>RTP: For the 28-day randomized treatment study phase, the Full Analysis Set (FAS) will include all patients who are randomized to the 28-day randomized treatment study phase.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="10.80"/>
                    <measurement group_id="B2" value="66.7" spread="11.40"/>
                    <measurement group_id="B3" value="68.0" spread="10.18"/>
                    <measurement group_id="B4" value="69.4" spread="10.26"/>
                    <measurement group_id="B5" value="67.7" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>All subjects in RTP took part in OLP. Thus, the Totals are calculated using replicated measurements.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>All subjects in RTP took part in OLP. Thus, the Totals are calculated using replicated measurements.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="511"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>All subjects in RTP took part in OLP. Thus, the Totals are calculated using replicated measurements.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Country</title>
          <description>All subjects in RTP took part in OLP. Thus, the Totals are calculated using replicated measurements.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Japan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Korea</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="235"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Russia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Taiwan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Square Mean S-K Level on Days 8-29</title>
        <description>Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment study phase day 8-29.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Square Mean S-K Level on Days 8-29</title>
          <description>Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.811" lower_limit="4.685" upper_limit="4.940"/>
                    <measurement group_id="O3" value="4.381" lower_limit="4.265" upper_limit="4.501"/>
                    <measurement group_id="O4" value="5.321" lower_limit="5.155" upper_limit="5.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Results derived from a mixed effects model of log-transformed S-K levels. Fixed effects are: treatment group; visit; treatment-by-visit interaction; baseline S-K values (OLP and RTP); baseline eGFR; age category; country; baseline RAAS inhibitor, chronic kidney disease, heart failure, and diabetes mellitus statuses. Patient is a random effect. p-values given are for differences of LSMEANS. The back-transformation is to the original scale of the S-K measurement.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.904</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.876</ci_lower_limit>
            <ci_upper_limit>0.933</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.823</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.797</ci_lower_limit>
            <ci_upper_limit>0.850</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving Normokalemia</title>
        <description>Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours. The results in the table below are presented for OLP. (h=hours).</description>
        <time_frame>Through 48-hour initial phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving Normokalemia</title>
          <description>Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours. The results in the table below are presented for OLP. (h=hours).</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normokalemic at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Normokalemic at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing at 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normokalemic at 48h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Normokalemic at 48h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing at 48h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exponential Rate of Change in S-K Levels</title>
        <description>Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase. The results in the table below are presented for OLP.</description>
        <time_frame>Through 48-hour initial phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Exponential Rate of Change in S-K Levels</title>
          <description>Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase. The results in the table below are presented for OLP.</description>
          <population>Full Analysis Set</population>
          <units>log(mmol/L)/h</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in S-K Levels</title>
        <description>Absolute change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.</description>
        <time_frame>Through 48-hour initial phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in S-K Levels</title>
          <description>Absolute change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OLP Day 1-1h post-first dose absolute change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 1-2h post-first dose absolute change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 1-4h post-first dose absolute change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 2-24h absolute change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 2-1h post-first dose absolute change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 3-48h absolute change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in S-K Levels</title>
        <description>Percentage change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.</description>
        <time_frame>Through 48-hour initial phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in S-K Levels</title>
          <description>Percentage change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.</description>
          <population>Full Analysis Set</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OLP Day 1-1h post-first dose percentage change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.26" spread="7.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 1-2h post-first dose percentage change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.29" spread="7.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 1-4h post-first dose percentage change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.88" spread="8.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 2-24h percentage change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.08" spread="6.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 2-1h post-first dose percentage change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.84" spread="7.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLP Day 3-48h percentage change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.16" spread="7.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Remaining Normokalemic</title>
        <description>The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment study phase day 8-29.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Remaining Normokalemic</title>
          <description>The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment group comparisons were made using a logistic regression model containing the following covariates: treatment group; both baseline S-K values (48-hours open-label initial phase and double-blind randomized phase); baseline eGFR (during 48-hour open-label initial phase); age category (&lt;55, 55-64, &gt;=65 years); country; baseline RAAS inhibitor, chronic kidney disease, heart failure, and diabetes mellitus statuses.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.3436</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6866</ci_lower_limit>
            <ci_upper_limit>14.9782</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>18.1876</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.1591</ci_lower_limit>
            <ci_upper_limit>46.2054</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Normokalemic Patients at Day 1 Through Day 29/Exit</title>
        <description>The proportion of patients who are normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at Day 1 through Day 29/Exit in randomization phase. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Normokalemic Patients at Day 1 Through Day 29/Exit</title>
          <description>The proportion of patients who are normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at Day 1 through Day 29/Exit in randomization phase. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/Exit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Patients Remain Normokalemic</title>
        <description>The number of days patients remain normokalemic during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Patients Remain Normokalemic</title>
          <description>The number of days patients remain normokalemic during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>Day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.810" spread="1.113"/>
                    <measurement group_id="O3" value="15.623" spread="1.143"/>
                    <measurement group_id="O4" value="3.543" spread="1.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Results derived from a linear regression model with the following covariates: treatment group; baseline S-K values (Open-label phase and Randomized treatment phase); baseline eGFR; age category; country; baseline RAAS inhibitor, chronic kidney disease, heart failure, and diabetes mellitus statuses.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.266</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.318</ci_lower_limit>
            <ci_upper_limit>10.214</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.118</ci_lower_limit>
            <ci_upper_limit>15.040</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in S-K Levels</title>
        <description>The mean change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in S-K Levels</title>
          <description>The mean change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.03" spread="0.354"/>
                    <measurement group_id="O3" value="-0.09" spread="0.372"/>
                    <measurement group_id="O4" value="0.17" spread="0.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.23" spread="0.478"/>
                    <measurement group_id="O3" value="-0.08" spread="0.439"/>
                    <measurement group_id="O4" value="0.60" spread="0.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.44" spread="0.487"/>
                    <measurement group_id="O3" value="0.00" spread="0.489"/>
                    <measurement group_id="O4" value="0.91" spread="0.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.53" spread="0.560"/>
                    <measurement group_id="O3" value="0.05" spread="0.573"/>
                    <measurement group_id="O4" value="0.97" spread="0.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.54" spread="0.584"/>
                    <measurement group_id="O3" value="0.04" spread="0.564"/>
                    <measurement group_id="O4" value="0.85" spread="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.56" spread="0.578"/>
                    <measurement group_id="O3" value="0.05" spread="0.576"/>
                    <measurement group_id="O4" value="0.97" spread="0.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.47" spread="0.555"/>
                    <measurement group_id="O3" value="0.10" spread="0.613"/>
                    <measurement group_id="O4" value="0.93" spread="0.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.51" spread="0.581"/>
                    <measurement group_id="O3" value="0.05" spread="0.639"/>
                    <measurement group_id="O4" value="1.01" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.47" spread="0.586"/>
                    <measurement group_id="O3" value="0.02" spread="0.665"/>
                    <measurement group_id="O4" value="1.02" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.92" spread="0.661"/>
                    <measurement group_id="O3" value="0.77" spread="0.695"/>
                    <measurement group_id="O4" value="0.88" spread="0.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.28" spread="0.544"/>
                    <measurement group_id="O3" value="-1.36" spread="0.515"/>
                    <measurement group_id="O4" value="-1.07" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.08" spread="0.552"/>
                    <measurement group_id="O3" value="-1.35" spread="0.601"/>
                    <measurement group_id="O4" value="-0.64" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.87" spread="0.578"/>
                    <measurement group_id="O3" value="-1.28" spread="0.634"/>
                    <measurement group_id="O4" value="-0.34" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.79" spread="0.603"/>
                    <measurement group_id="O3" value="-1.21" spread="0.671"/>
                    <measurement group_id="O4" value="-0.28" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.77" spread="0.604"/>
                    <measurement group_id="O3" value="-1.23" spread="0.643"/>
                    <measurement group_id="O4" value="-0.40" spread="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.74" spread="0.639"/>
                    <measurement group_id="O3" value="-1.20" spread="0.672"/>
                    <measurement group_id="O4" value="-0.30" spread="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.84" spread="0.597"/>
                    <measurement group_id="O3" value="-1.15" spread="0.730"/>
                    <measurement group_id="O4" value="-0.38" spread="0.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.79" spread="0.687"/>
                    <measurement group_id="O3" value="-1.21" spread="0.762"/>
                    <measurement group_id="O4" value="-0.28" spread="0.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.82" spread="0.604"/>
                    <measurement group_id="O3" value="-1.24" spread="0.734"/>
                    <measurement group_id="O4" value="-0.27" spread="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.39" spread="0.649"/>
                    <measurement group_id="O3" value="-0.50" spread="0.725"/>
                    <measurement group_id="O4" value="-0.36" spread="0.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change in S-K Levels</title>
        <description>The mean percentage change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in S-K Levels</title>
          <description>The mean percentage change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.00" spread="8.459"/>
                    <measurement group_id="O3" value="-1.74" spread="7.981"/>
                    <measurement group_id="O4" value="4.19" spread="10.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.51" spread="11.337"/>
                    <measurement group_id="O3" value="-1.52" spread="9.691"/>
                    <measurement group_id="O4" value="14.19" spread="13.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.26" spread="11.340"/>
                    <measurement group_id="O3" value="0.16" spread="11.062"/>
                    <measurement group_id="O4" value="21.55" spread="15.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.41" spread="13.113"/>
                    <measurement group_id="O3" value="1.60" spread="13.205"/>
                    <measurement group_id="O4" value="22.87" spread="16.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.50" spread="13.378"/>
                    <measurement group_id="O3" value="1.27" spread="12.937"/>
                    <measurement group_id="O4" value="20.15" spread="14.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="13.12" spread="13.180"/>
                    <measurement group_id="O3" value="1.70" spread="13.139"/>
                    <measurement group_id="O4" value="22.77" spread="14.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11.04" spread="12.993"/>
                    <measurement group_id="O3" value="2.66" spread="14.042"/>
                    <measurement group_id="O4" value="22.28" spread="18.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.02" spread="13.616"/>
                    <measurement group_id="O3" value="1.49" spread="14.441"/>
                    <measurement group_id="O4" value="23.63" spread="15.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11.34" spread="13.821"/>
                    <measurement group_id="O3" value="0.87" spread="15.084"/>
                    <measurement group_id="O4" value="23.99" spread="15.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS percentage change from RTP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="21.62" spread="16.027"/>
                    <measurement group_id="O3" value="17.76" spread="16.266"/>
                    <measurement group_id="O4" value="20.70" spread="17.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-22.12" spread="8.679"/>
                    <measurement group_id="O3" value="-23.55" spread="7.652"/>
                    <measurement group_id="O4" value="-18.51" spread="9.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-18.77" spread="9.347"/>
                    <measurement group_id="O3" value="-23.31" spread="9.230"/>
                    <measurement group_id="O4" value="-10.96" spread="9.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-15.01" spread="9.627"/>
                    <measurement group_id="O3" value="-22.01" spread="10.037"/>
                    <measurement group_id="O4" value="-5.41" spread="11.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-13.55" spread="9.891"/>
                    <measurement group_id="O3" value="-20.84" spread="10.981"/>
                    <measurement group_id="O4" value="-4.57" spread="10.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-13.35" spread="10.170"/>
                    <measurement group_id="O3" value="-21.18" spread="10.351"/>
                    <measurement group_id="O4" value="-6.63" spread="9.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-12.79" spread="11.339"/>
                    <measurement group_id="O3" value="-20.67" spread="10.834"/>
                    <measurement group_id="O4" value="-4.89" spread="9.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-14.49" spread="10.158"/>
                    <measurement group_id="O3" value="-19.67" spread="11.723"/>
                    <measurement group_id="O4" value="-6.43" spread="9.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-13.35" spread="11.599"/>
                    <measurement group_id="O3" value="-20.75" spread="12.360"/>
                    <measurement group_id="O4" value="-4.74" spread="9.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-14.09" spread="9.949"/>
                    <measurement group_id="O3" value="-21.42" spread="11.659"/>
                    <measurement group_id="O4" value="-4.61" spread="8.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS percentage change from OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="99"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-6.57" spread="11.199"/>
                    <measurement group_id="O3" value="-8.54" spread="12.405"/>
                    <measurement group_id="O4" value="-5.95" spread="11.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hyperkalemic Patients</title>
        <description>The results represent number of hyperkalemic patients during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hyperkalemic Patients</title>
          <description>The results represent number of hyperkalemic patients during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Results derived from a Cox Proportional Hazards model with the following covariates: treatment group, both baseline S-K values (48-hours open-label initial phase and double-blind randomized phase), baseline eGFR, age category (&lt;55, 55-64, &gt;=65 years), country, baseline RAAS inhibitor, chronic kidney, disease heart failure, and diabetes mellitus statuses.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.443</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2954</ci_lower_limit>
            <ci_upper_limit>0.6631</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.158</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0992</ci_lower_limit>
            <ci_upper_limit>0.2508</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in S-Aldosterone and P Renin Levels</title>
        <description>The mean changes from OLP baseline in S-Aldosterone and P-Renin levels. The results in the table below are presented for RTP.</description>
        <time_frame>Through 28-day randomized treatment phase.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in S-Aldosterone and P Renin Levels</title>
          <description>The mean changes from OLP baseline in S-Aldosterone and P-Renin levels. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 S-Aldosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-112.69" spread="178.358"/>
                    <measurement group_id="O3" value="-85.63" spread="118.017"/>
                    <measurement group_id="O4" value="-98.54" spread="168.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 S-Aldosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-91.75" spread="179.791"/>
                    <measurement group_id="O3" value="-96.37" spread="108.002"/>
                    <measurement group_id="O4" value="39.78" spread="152.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 S-Aldosterone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-102.70" spread="212.187"/>
                    <measurement group_id="O3" value="-90.22" spread="91.149"/>
                    <measurement group_id="O4" value="41.07" spread="198.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 P-Renin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.23" spread="1.158"/>
                    <measurement group_id="O3" value="-0.26" spread="1.913"/>
                    <measurement group_id="O4" value="-0.30" spread="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 P-Renin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.39" spread="1.350"/>
                    <measurement group_id="O3" value="-1.09" spread="4.732"/>
                    <measurement group_id="O4" value="0.60" spread="3.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 P-Renin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.27" spread="1.008"/>
                    <measurement group_id="O3" value="-1.56" spread="4.165"/>
                    <measurement group_id="O4" value="-0.25" spread="2.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Health State (EQ-5D) Questionnaire</title>
        <description>Evaluate health state of patients using EQ-5D questionnaire. This scale is numbered from 0 to 100. 0 means the worst health you can imagine. 100 means the best health you can imagine. The results in the table below are presented for RTP.</description>
        <time_frame>Through study completion, an average of 37 days.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
            <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
            <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O3">
            <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
            <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Health State (EQ-5D) Questionnaire</title>
          <description>Evaluate health state of patients using EQ-5D questionnaire. This scale is numbered from 0 to 100. 0 means the worst health you can imagine. 100 means the best health you can imagine. The results in the table below are presented for RTP.</description>
          <population>Full Analysis Set</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OLP baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="75.0" spread="16.44"/>
                    <measurement group_id="O3" value="74.3" spread="17.44"/>
                    <measurement group_id="O4" value="72.7" spread="17.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="86"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="77.6" spread="16.50"/>
                    <measurement group_id="O3" value="76.9" spread="16.08"/>
                    <measurement group_id="O4" value="76.6" spread="14.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 28-day randomized treatment study phase day 8-29</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sodium Zirconium Cyclosilicate (ZS) 10g Tid</title>
          <description>Suspension administered 10g orally 3 times per day for the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="E2">
          <title>Sodium Zirconium Cyclosilicate (ZS) 5g</title>
          <description>Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="E3">
          <title>Sodium Zirconium Cyclosilicate (ZS) 10g</title>
          <description>Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

